Becton, Dickinson and Company $BDX Position Lowered by Truist Financial Corp

Truist Financial Corp trimmed its position in Becton, Dickinson and Company (NYSE:BDX) by 12.0% in the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor owned 82,211 shares of the medical instruments supplier’s stock after selling 11,189 shares during the period. Truist Financial Corp’s holdings in Becton, Dickinson and Company were worth $15,955,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently bought and sold shares of the company. Avidian Wealth Enterprises LLC bought a new position in Becton, Dickinson and Company during the 4th quarter worth approximately $205,000. Strs Ohio raised its holdings in shares of Becton, Dickinson and Company by 0.5% during the fourth quarter. Strs Ohio now owns 302,819 shares of the medical instruments supplier’s stock worth $58,768,000 after purchasing an additional 1,389 shares during the period. Composition Wealth LLC raised its holdings in shares of Becton, Dickinson and Company by 7.8% during the fourth quarter. Composition Wealth LLC now owns 2,039 shares of the medical instruments supplier’s stock worth $396,000 after purchasing an additional 148 shares during the period. Danske Bank A S lifted its position in shares of Becton, Dickinson and Company by 56.9% in the 4th quarter. Danske Bank A S now owns 289,926 shares of the medical instruments supplier’s stock worth $56,266,000 after buying an additional 105,091 shares during the last quarter. Finally, GenTrust LLC acquired a new position in shares of Becton, Dickinson and Company in the 4th quarter valued at about $205,000. Institutional investors and hedge funds own 86.97% of the company’s stock.

Becton, Dickinson and Company Stock Performance

Shares of BDX stock opened at $152.83 on Friday. The company has a market capitalization of $43.52 billion, a price-to-earnings ratio of 24.93, a P/E/G ratio of 10.32 and a beta of 0.22. Becton, Dickinson and Company has a 1-year low of $127.59 and a 1-year high of $187.35. The company has a current ratio of 1.05, a quick ratio of 0.58 and a debt-to-equity ratio of 0.67. The stock’s fifty day simple moving average is $158.49 and its 200-day simple moving average is $181.08.

Becton, Dickinson and Company (NYSE:BDX) last posted its quarterly earnings results on Thursday, May 7th. The medical instruments supplier reported $2.90 EPS for the quarter, beating the consensus estimate of $2.77 by $0.13. Becton, Dickinson and Company had a net margin of 8.01% and a return on equity of 15.76%. The business had revenue of $4.71 billion for the quarter, compared to analysts’ expectations of $4.67 billion. During the same period in the previous year, the company posted $3.35 EPS. Becton, Dickinson and Company’s revenue was up 5.2% on a year-over-year basis. Becton, Dickinson and Company has set its FY 2026 guidance at 12.520-12.720 EPS. On average, sell-side analysts predict that Becton, Dickinson and Company will post 12.53 earnings per share for the current fiscal year.

Becton, Dickinson and Company Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, June 30th. Shareholders of record on Tuesday, June 9th will be paid a $1.05 dividend. The ex-dividend date is Tuesday, June 9th. This represents a $4.20 dividend on an annualized basis and a yield of 2.7%. Becton, Dickinson and Company’s payout ratio is 68.52%.

Becton, Dickinson and Company declared that its Board of Directors has authorized a stock repurchase plan on Tuesday, January 27th that allows the company to buyback $10.00 million in outstanding shares. This buyback authorization allows the medical instruments supplier to buy up to 0% of its shares through open market purchases. Shares buyback plans are typically an indication that the company’s board believes its shares are undervalued.

Wall Street Analysts Forecast Growth

A number of brokerages recently weighed in on BDX. Royal Bank Of Canada set a $175.00 price objective on shares of Becton, Dickinson and Company in a research report on Tuesday, April 14th. Piper Sandler decreased their target price on shares of Becton, Dickinson and Company from $170.00 to $159.00 and set a “neutral” rating for the company in a research report on Friday, April 17th. Evercore started coverage on shares of Becton, Dickinson and Company in a research note on Monday. They set an “outperform” rating and a $180.00 price objective on the stock. The Goldman Sachs Group started coverage on Becton, Dickinson and Company in a research report on Friday, April 10th. They issued a “neutral” rating and a $167.00 target price for the company. Finally, JPMorgan Chase & Co. lowered their target price on Becton, Dickinson and Company from $190.00 to $175.00 and set a “neutral” rating on the stock in a report on Tuesday, February 10th. Seven research analysts have rated the stock with a Buy rating and nine have issued a Hold rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $186.57.

Key Stories Impacting Becton, Dickinson and Company

Here are the key news stories impacting Becton, Dickinson and Company this week:

• Positive Sentiment: Q2 results beat consensus: revenue $4.71B (+5.2% YoY) and adjusted EPS $2.90 vs. $2.77 est; company raised FY2026 adjusted EPS to $12.52–$12.72 (slightly above consensus). BD Reports Second Quarter Fiscal 2026 Financial Results
• Positive Sentiment: Capital allocation boost: BD executed a $2.0B accelerated share repurchase and retired $2.1B of debt in the quarter, supporting EPS accretion and balance-sheet improvement. BD Reports Second Quarter Fiscal 2026 Financial Results
• Positive Sentiment: Management reinforcement: BD appointed Vitor Roque as CFO, a leadership move investors view as positive for execution and guidance credibility. BD Appoints Vitor Roque Chief Financial Officer
• Neutral Sentiment: Business mix and commentary were mixed — company reaffirmed low-single-digit revenue growth while highlighting strength in drug‑delivery devices and surgical equipment (supporting margins). BD forecasts FY 2026 adjusted EPS…
• Neutral Sentiment: Options market shows elevated activity — some traders are positioning for larger near-term moves, which can increase intraday volatility but is not a directional confirmation. Is the Options Market Predicting a Spike in Becton Dickinson Stock?
• Neutral Sentiment: Earnings-call highlights and analyst notes summarize mixed headwinds but an overall confidence boost from the raised EPS outlook. Becton Dickinson Lifts EPS Outlook Amid Mixed Headwinds
• Negative Sentiment: Year-over-year EPS decline: adjusted EPS of $2.90 compares to $3.35 a year ago, highlighting that while results topped expectations, profitability is still below last year’s level — a potential concern for some investors. BD’s (NYSE:BDX) Q1 CY2026 sales beat estimates

Insiders Place Their Bets

In other news, Director Bertram L. Scott sold 953 shares of the firm’s stock in a transaction dated Wednesday, February 18th. The stock was sold at an average price of $182.61, for a total transaction of $174,027.33. Following the completion of the sale, the director directly owned 36,763 shares of the company’s stock, valued at $6,713,291.43. This trade represents a 2.53% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Over the last quarter, insiders sold 1,102 shares of company stock valued at $198,909. Corporate insiders own 0.40% of the company’s stock.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.